CSIMarket
 


Aslan Pharmaceuticals Limited  (ASLN)
Other Ticker:  
 

Aslan Pharmaceuticals Limited's Quick Ratio

ASLN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the forth quarter 2022, Quick Ratio deteriorated to 1.92 above company average Quick Ratio.

Within Major Pharmaceutical Preparations industry 395 other companies have achieved higher Quick Ratio than Aslan Pharmaceuticals Limited in forth quarter 2022. While Quick Ratio total ranking has improved so far during the IV Quarter 2022 to 1613, from total ranking in the third quarter 2022 at 1778.

Explain Quick Ratio?
How much Cash & cash equivalents ASLN´s has?
What are ASLN´s Current Liabilities?


ASLN Quick Ratio (Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Current Liabilities Change -3.89 % -3.89 % -3.89 % -3.89 % 70.63 %
Y / Y Cash & cash equivalent Change -36.89 % -36.89 % -36.89 % -36.89 % 529.47 %
Quick Ratio MRQ 1.92 1.92 1.92 1.92 2.92
ASLN's Total Ranking # 1613 # 1778 # 1879 # 2009 # 1573
Seq. Current Liabilities Change 0 % 0 % 0 % -3.89 % 0 %
Seq. Cash & cash equivalent Change 0 % 0 % 0 % -36.89 % 0 %



Quick Ratio forth quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 396
Healthcare Sector # 703
Overall Market # 1575


Quick Ratio Statistics
High Average Low
2.92 1.8 0.79
(Dec 31 2021)   (Dec 31 2020)




Financial Statements
Aslan Pharmaceuticals Limited's Current Liabilities $ 30 Millions Visit ASLN's Balance sheet
Aslan Pharmaceuticals Limited's Cash & cash equivalent $ 57 Millions Visit ASLN's Balance sheet
Source of ASLN's Sales Visit ASLN's Sales by Geography


Cumulative Aslan Pharmaceuticals Limited's Quick Ratio

ASLN's Quick Ratio for the trailling 12 Months

ASLN Quick Ratio

(Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Current Liabilities TTM Growth -3.89 % -3.89 % -3.89 % -3.89 % 70.63 %
Y / Y Cash & cash equivalent TTM Growth -36.89 % -36.89 % -36.89 % -36.89 % 529.47 %
Quick Ratio TTM 1.92 2.18 2.43 2.68 2.92
Total Ranking TTM # 1370 # 4385 # 4738 # 4688 # 1352
Seq. Current Liabilities TTM Growth 0 % 0 % 0 % -3.89 % 0 %
Seq. Cash & cash equivalent TTM Growth 0 % 0 % 0 % -36.89 % 0 %


On the trailing twelve months basis In spite of the year on year decrease in ASLN's Current Liabilities to $29.66 millions, cumulative Quick Ratio to 1.92 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 399 other companies have achieved higher Quick Ratio than Aslan Pharmaceuticals Limited. While Quick Ratio overall ranking has improved so far to 1370, from total ranking during the twelve months ending third quarter 2022 at 4385.

Explain Quick Ratio?
How much Cash & cash equivalents ASLN´s has?
What are ASLN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 400
Healthcare Sector # 709
Within the Market # 1370


trailing twelve months Quick Ratio Statistics
High Average Low
2.92 1.91 0.79
(Dec 31 2021)   (Dec 31 2020)




Companies with similar Quick Ratio in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2022 MRQ Cash & cash equivalentDec 31 2022 MRQ Current Liabilities
Reviva Pharmaceuticals Holdings Inc   5.26 $ 18.520  Millions$ 3.520  Millions
Gain Therapeutics inc  5.24 $ 20.139  Millions$ 3.841  Millions
Exicure Inc   5.23 $ 8.577  Millions$ 1.639  Millions
Arcus Biosciences Inc   5.23 $ 1,009.000  Millions$ 193.000  Millions
Gossamer Bio Inc   5.19 $ 255.678  Millions$ 49.230  Millions
Catalyst Pharmaceuticals Inc   5.18 $ 298.395  Millions$ 57.588  Millions
Biohaven Ltd   5.17 $ 465.341  Millions$ 90.021  Millions
Blueprint Medicines Corporation  5.16 $ 944.992  Millions$ 183.234  Millions
Zymeworks Inc   5.15 $ 492.232  Millions$ 95.625  Millions
Eyenovia inc   5.09 $ 22.983  Millions$ 4.512  Millions
Beyondspring Inc   5.07 $ 37.268  Millions$ 7.352  Millions
Connect Biopharma Holdings Limited  5.06 $ 79.010  Millions$ 15.624  Millions
Spero Therapeutics Inc   5.04 $ 109.107  Millions$ 21.649  Millions
Vera Therapeutics Inc   4.99 $ 114.653  Millions$ 22.955  Millions
Unity Biotechnology Inc   4.83 $ 94.795  Millions$ 19.620  Millions
Amarin Corp Plcuk  4.80 $ 309.884  Millions$ 64.602  Millions
Inmed Pharmaceuticals Inc   4.79 $ 11.496  Millions$ 2.401  Millions
Hoth Therapeutics Inc   4.78 $ 6.638  Millions$ 1.388  Millions
I mab  4.75 $ 500.121  Millions$ 105.191  Millions
Enveric Biosciences Inc   4.73 $ 17.724  Millions$ 3.747  Millions
Evelo Biosciences Inc   4.73 $ 47.940  Millions$ 10.136  Millions
Corbus Pharmaceuticals Holdings Inc   4.68 $ 59.197  Millions$ 12.640  Millions
Decibel Therapeutics Inc   4.66 $ 104.561  Millions$ 22.442  Millions
Siga Technologies Inc  4.59 $ 98.791  Millions$ 21.518  Millions
Revance Therapeutics Inc   4.50 $ 340.707  Millions$ 75.682  Millions
Proqr Therapeutics N v   4.49 $ 106.148  Millions$ 23.645  Millions
Arbutus Biopharma Corp  4.47 $ 146.913  Millions$ 32.857  Millions
Galmed Pharmaceuticals Ltd   4.46 $ 13.785  Millions$ 3.094  Millions
Karyopharm Therapeutics Inc   4.43 $ 279.031  Millions$ 63.036  Millions
Acurx Pharmaceuticals inc   4.42 $ 9.112  Millions$ 2.062  Millions

Date modified: 2023-03-26T05:28:45+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com